Since the identification of some alterations in the expression of both epidermal growth factor/epidermal growth factor receptor (EGF/EGFR) in lung cancer pathogenesis, several therapeutic targeting agents have been employed for the treatment of lung tumors overexpressing these molecules [5, 6]. This evidence concerns the gene EGF and lung carcinoma.